Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Total Current Assets
All assets expected to be converted to cash or used up within one year.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 132.4% from a year ago
Total current assets stood at $63.55M at the end of Q1 FY2026, up 132.4% from a year earlier and up 29.8% from the prior quarter. Over 3 fiscal years it compounded at +164.6% a year.
Context
- Total current assets amounted to 98.7% of total assets at the end of Q1 FY2026, up 0.8 pp from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +132.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 48.96M USD
- Year-over-year change
- +58.2%
- 4-year CAGR
- +27.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.96M | +58.2% |
| FY2024 | 2024-12-31 | 30.95M | +131.0% |
| FY2023 | 2023-12-31 | 13.4M | +406.8% |
| FY2022 | 2022-12-31 | 2.64M | -85.6% |
| FY2021 | 2021-12-31 | 18.41M | — |
Total Current Assets vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +132.4% is the 3rd highest of 10, against a peer median of +27.8%.
- Total current assets amounts to 98.7% of total assets for UNCY, versus a peer median of 96.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $235.34M USD | +750.9% | -15.0% | 100.0% | |
| Mar 2026 | $188.76M USD | +894.8% | -43.4% | 99.5% | |
| Mar 2026 | $131.7M USD | +110.2% | +11.0% | 73.1% | |
| Mar 2026 | $102.2M USD | +97.8% | — | 96.9% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $99.22M USD | -34.4% | -3.0% | 92.0% |
| Mar 2026 | $95.78M USD | -41.4% | -22.4% | 99.2% | |
| Mar 2026 | $63.55M USD | +132.4% | +164.6% | 98.7% | |
| Mar 2026 | $46.32M USD | +3.7% | -21.0% | 99.9% | |
CBUSCibus, Inc. | Mar 2026 | $33.07M USD | +27.8% | +42.9% | 10.2% |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$18.96M CAD | -8.6% | -20.6% | 81.9% |
| Peer median (excluding UNCY) | — | +27.8% | -17.8% | 96.9% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.